Fecal β-D-galactosidase production and Bifidobacteria are decreased in Crohn's disease

Digestive Diseases and Sciences

Volumn 42, Issue 4, 1997, Pages 817-822

  Favier, C ^b   Neut, C ^b   Mizon, C ^a   Cortot, A ^b   Colombel, J F ^b   Mizon, J ^b  

^a UNIV LILLE   (France)

^b NONE

Author keywords

Bifidobacteria; Crohn's disease; D galactosidase

Indexed keywords

AZATHIOPRINE; BETA GALACTOSIDASE; CORTICOSTEROID; METHOTREXATE; SALAZOSULFAPYRIDINE;

ADOLESCENT; ADULT; ARTICLE; BACTEROIDES; CELL COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; ENZYME ACTIVITY; FECES; FEMALE; HUMAN; HUMAN TISSUE; INTESTINE FLORA; LACTOBACILLUS; LACTOBACILLUS BIFIDUS; MALE; PARENTERAL NUTRITION; PRIORITY JOURNAL;

EID: 0030906468     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018876400528     Document Type: Article

References (26)

1. Sartor RB: The role of normal enteric bacteria and bacterial products in chronic intestinal inflammation. In Inflammatory Bowel Disease. GNJ Tygtat, JFW Bartelsman. SJH van Deventer (eds). Dordrecht, Kluwer Academic Publishers, 1995, pp 519-527
2. Gorbach SL, Nahas L, Plaut AG, Weinstein L, Patterson JF, Levitan R: Studies of intestinal microflora. Gastroenterology 54:575-587, 1968
3. West B, Lendrum R, Hill MJ, Walker G: Effects of sulfasalazine (Salazopyrin) on fecal flora in patients with inflammatory bowel disease. Gut 15:960-965, 1974
4. Keighley MRB, Arabi Y, Dimock F, Burdon DW, Allan RN, Alexander-Williams J: Influence of inflammatory bowel disease on intestinal microflora. Gut 19:1099-1104, 1978
5. Krook A, Danielsson D, Kjellander J, Jarnerot G: The effect of metronidazole and sulfasalazine on the fecal flora in patients with Crohn's disease. Scand J Gastroenterol 16:183-192, 1981
6. Wensinck F, Custers-van Lieshout LMC, Poppelaars-Kustermans PAJ, Schröder AM: The fecal flora of patients with Crohn's disease. J Hyg Camb 87:1-12, 1981
7. Ruseler-van Embden JGH, Both Patoir HC: Anaerobic gramnegative fecal flora in patients with Crohn's disease and healthy subjects. Antonie van Leeuwenhoek 49:125-132, 1983
8. Hudson MJ, Hill MJ, Elliot PR, Berghouse LM, Burnham WR, Lennard-Jones JE: The microbial flora of the rectal mucosa and feccs of patients with Crohn's disease before and during antimicrobial chemotherapy. J Med Microbiol 18:335-345, 1984
9. Van de Merwe JP, Schröder AM, Wensinck F, Hazenberg MP: The obligate anaerobic fecal flora of patients with Crohn's disease and their first-degree relatives. Scand J Gastroenterol 23:1125-1131, 1988
10. Giaffer MH, Holdsworth CD, Duerden BI: The assessment of fecal flora in patients with inflammatory bowel disease by a simplified bacteriological technique. J Med Microbiol 35:238-243, 1991
11. Gilberts ECAM, Greenstein AJ, Katsel P, Harpaz N, Greenstein RJ: Molecular evidence for two forms of Crohn disease. Proc Natl Acad Sci USA 91:12721-12724, 1994
12. Rhodes JM, Gallimore R, Elias E, Allan RN, Kennedy JF: Fecal mucus degrading glycosidases in ulcerative colitis and Crohn's disease. Gut 26:761-765, 1985
13. Leijonmarck CE, Bergstrand LO, Carlstedt-Duke B, Gustafsson A, Midtvedt AC, Norin KE, Saxerholt H, Midtvedt T: Total parenteral nutrition and the function of the intestinal microflora in Crohn's disease. Scand J Gastroenterol 23:59-64, 1988
14. Ruseler-van Embden JGH, van Lieshout LMC: Increased fecal glycosidases in patients with Crohn's disease. Digestion 37:43-50, 1987
15. El Yamani J, Mizon C, Capon C, Colombel JF, Fournet B, Cortot A, Mizon J: Decreased fecal exoglycosidase activities identify a subset of patients with active Crohn's disease. Clin Sci 83:409-415, 1992
16. Carrette O, Favier C, Mizon C, Neut C, Cortot A, Colombel JF, Mizon J: The bacterial enzymes used for colon-specific drug delivery are decreased in active Crohn's disease. Dig Dis Sci 40:2641-2646, 1995
17. Canva Delcambre V, Soenen V, Mizon C, Cortot A, Mizon J, Colombel JF: L'activité β-D-galactosidasique fécale est diminuée au cours de la maladie de Crohn. Gastroenterol Clin Biol 17:718-722, 1993
18. ,8. Best WR, Beckel JM, Singleton JW, Kern F Jr: Development of Crohn's disease activity index. Gastroenterology 70:439-444, 1976
19. Favier C, Neut C, Mizon C, Cortot A, Colombel JF, Mizon J: Research and identification of human fecal anaerobic bacteria producing β-D-galactosidase: A new methodology. J Microbiol Methods 27:25-31, 1996
20. Beerens H: An elective and selective isolation medium for Bifidobacterium spp. Lett Appl Microbiol 11:155-157, 1990
21. Livingston SJ, Kominos SD, Lee RB: New medium for selection and presumptive identification of the Bacteroides fragilis group. J Clin Microbiol 7:448-453, 1978
22. MacFarlane GT, Hay S, Gihson GR: Influence of mucin on glycosidase, protease and arylamidase activities of human gut bacteria grown in a 3-stage continuous culture system. J Appl Bacteriol 66:407-417, 1989
23. Ikeda N, Saito Y, Shimizu J, Ochi A, Mizutani J, Watabe J: Variations in concentrations of bacterial metabolites, enzyme activities, moisture, pH and bacterial composition between and within individuals in feces of seven healthy adults. J Appl Bacteriol 77:185-194, 1994
24. Gibson GR, Wang X: Regulatory effects of bifidobacteria on the growth of other colonic bacteria. J Appl Bacteriol 77:412-420, 1994
25. Gibson GR, Roberfroid MB: Dietary modulation of the human colonic microbiota: Introducing the concept of prebiotics. J Nutr 125:1401-1412, 1995
26. Liao W, Cui XS, Jin XY, Florén CH: Lactulose - a potential drug for the treatment of inflammatory bowel disease. Med Hypoth 43:234-238, 1994